Jpmorgan Chase & CO Chroma Dex Corp. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Chroma Dex Corp. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 331,916 shares of CDXC stock, worth $1.82 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
331,916
Previous 298,766
11.1%
Holding current value
$1.82 Million
Previous $815,000
48.59%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding CDXC
# of Institutions
94Shares Held
17.2MCall Options Held
66.7KPut Options Held
8.2K-
Vanguard Group Inc Valley Forge, PA3.43MShares$18.8 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.12MShares$17.1 Million0.0% of portfolio
-
Tieton Capital Management, LLC Yakima, WA2.96MShares$16.2 Million5.59% of portfolio
-
Iconiq Capital, LLC San Francisco, CA1.3MShares$7.12 Million0.1% of portfolio
-
Geode Capital Management, LLC Boston, MA1.15MShares$6.31 Million0.0% of portfolio
About ChromaDex Corp.
- Ticker CDXC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,350,896
- Market Cap $375M
- Description
- ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingre...